MA39313B1 - Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers - Google Patents

Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers

Info

Publication number
MA39313B1
MA39313B1 MA39313A MA39313A MA39313B1 MA 39313 B1 MA39313 B1 MA 39313B1 MA 39313 A MA39313 A MA 39313A MA 39313 A MA39313 A MA 39313A MA 39313 B1 MA39313 B1 MA 39313B1
Authority
MA
Morocco
Prior art keywords
antibodies
present
treatment
various cancers
egfrvlll
Prior art date
Application number
MA39313A
Other languages
English (en)
Other versions
MA39313A1 (fr
Inventor
Douglas Macdonald
Gavin Thurston
Thomas Nittoli
Marcus Kelly
Frank Delfino
Jessica R Kirshner
Joel H Martin
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52875228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39313(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA39313A1 publication Critical patent/MA39313A1/fr
Publication of MA39313B1 publication Critical patent/MA39313B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps qui se lient au variant de classe iii du récepteur de facteur de croissance épidermique (egfrvlll) et des procédés d'utilisation desdits anticorps. Selon certains modes de réalisation, les anticorps de la présente invention se lient au egfrvlll humain avec une affinité élevée. Les anticorps selon la présente invention peuvent être des anticorps entièrement humains. La présente invention concerne encore des anticorps anti-egfrvlll conjugués à un agent cytotoxique, à un radionucléide, ou à une autre fraction préjudiciable à la croissance ou à la prolifération des cellules. Les anticorps selon l'invention sont utiles pour le traitement de divers cancers.
MA39313A 2014-03-11 2015-03-10 Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers MA39313B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461950963P 2014-03-11 2014-03-11
PCT/US2015/019722 WO2015138460A1 (fr) 2014-03-11 2015-03-10 ANTICORPS ANTI-EGFRvIII ET UTILISATIONS ASSOCIÉES

Publications (2)

Publication Number Publication Date
MA39313A1 MA39313A1 (fr) 2018-01-31
MA39313B1 true MA39313B1 (fr) 2018-12-31

Family

ID=52875228

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39313A MA39313B1 (fr) 2014-03-11 2015-03-10 Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers

Country Status (31)

Country Link
US (4) US9475875B2 (fr)
EP (1) EP3126388B1 (fr)
JP (1) JP6632984B2 (fr)
KR (1) KR102399005B1 (fr)
CN (1) CN106459199B (fr)
AU (1) AU2015229591B2 (fr)
BR (1) BR112016020752B1 (fr)
CA (1) CA2940685C (fr)
CL (1) CL2016002252A1 (fr)
CY (1) CY1121870T1 (fr)
DK (1) DK3126388T3 (fr)
EA (1) EA035809B1 (fr)
ES (1) ES2736126T3 (fr)
HR (1) HRP20191335T1 (fr)
HU (1) HUE045307T2 (fr)
IL (1) IL247407B (fr)
LT (1) LT3126388T (fr)
MA (1) MA39313B1 (fr)
ME (1) ME03525B (fr)
MX (1) MX373280B (fr)
MY (1) MY178160A (fr)
NZ (1) NZ724229A (fr)
PH (1) PH12016501680A1 (fr)
PL (1) PL3126388T3 (fr)
PT (1) PT3126388T (fr)
RS (1) RS59077B1 (fr)
SG (1) SG11201606979TA (fr)
SI (1) SI3126388T1 (fr)
SM (1) SMT201900439T1 (fr)
WO (1) WO2015138460A1 (fr)
ZA (1) ZA201605894B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
MY178160A (en) 2014-03-11 2020-10-06 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
US20160176962A1 (en) * 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017069628A2 (fr) * 2015-10-23 2017-04-27 Merus N.V. Molécules de liaison inhibant la croissance de cancer
EP3504328A1 (fr) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Modification de protéines de cellules hôtes
CA3036983A1 (fr) * 2016-11-21 2018-05-24 Cureab Gmbh Anticorps anti-gp73 et immunoconjugues
CN110650974B (zh) * 2017-02-10 2024-04-19 瑞泽恩制药公司 用于免疫-pet成像的放射性标记的抗-lag3抗体
BR112020000127A2 (pt) 2017-07-06 2020-07-07 Regeneron Pharmaceuticals, Inc. método para selecionar um hidrolisado de soja, e, glicoproteína
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
SI3665198T1 (sl) 2017-08-09 2025-06-30 Merus N.V. Protitelesa, ki vežejo egfr in cmet
KR102119783B1 (ko) * 2017-08-14 2020-06-08 사회복지법인 삼성생명공익재단 인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편
CN109912715A (zh) * 2017-12-13 2019-06-21 凯惠科技发展(上海)有限公司 一种EGFRvIII抗体及其偶联物、制备方法和应用
BR112020010615A2 (pt) 2017-12-22 2020-10-27 Regeneron Pharmaceuticals, Inc. produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema
MX2020008095A (es) 2018-01-31 2020-09-24 Regeneron Pharma Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos.
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
KR20200127979A (ko) 2018-02-28 2020-11-11 리제너론 파마슈티칼스 인코포레이티드 바이러스 오염물질을 확인하기 위한 시스템 및 방법
CA3246952A1 (en) 2018-03-19 2025-10-31 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
US11754569B2 (en) 2018-08-30 2023-09-12 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
PL3857237T3 (pl) 2019-01-16 2023-07-10 Regeneron Pharmaceuticals, Inc. Sposoby charakteryzowania mostka disiarczkowego
US12540186B2 (en) 2019-03-27 2026-02-03 National Research Council Of Canada Anti-EGFRvIII antibodies and antigen-binding fragments thereof
AU2020275406A1 (en) 2019-05-13 2021-11-18 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
AU2020299382A1 (en) * 2019-07-02 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind EGFRvIII and their use
IL291020B2 (en) 2019-09-24 2025-04-01 Regeneron Pharma Systems and methods for use in chromatography and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
MY207613A (en) 2019-11-25 2025-03-06 Regeneron Pharma Sustained release formulations using non-aqueous emulsions
US11835527B2 (en) 2020-01-21 2023-12-05 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
CN115698067A (zh) * 2020-04-24 2023-02-03 美勒斯公司 使用结合lgr5及egfr的抗体的癌症治疗
IL300828A (en) 2020-08-31 2023-04-01 Regeneron Pharma Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants
MX2023006077A (es) 2020-11-25 2023-06-06 Regeneron Pharma Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
US12350374B2 (en) 2020-12-17 2025-07-08 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
TW202233827A (zh) 2021-01-20 2022-09-01 美商再生元醫藥公司 改良細胞培養中蛋白質效價的方法
US20240228629A1 (en) * 2021-02-16 2024-07-11 City Of Hope Anti-domain iv egfr antibodies and uses thereof
AR125585A1 (es) 2021-03-03 2023-08-02 Regeneron Pharma Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
CA3211302A1 (fr) 2021-03-26 2022-09-29 Ross Kenyon Procedes et systemes pour developper des protocoles de melange
BR112023024984A2 (pt) 2021-06-01 2024-02-20 Regeneron Pharma Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
IL309048A (en) * 2021-06-22 2024-02-01 Regeneron Pharma Anti-EGFRVIII drug antibody conjugates and uses thereof
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
CA3232463A1 (fr) 2021-09-20 2023-03-23 Philip Mellors Procedes de controle de l'heterogeneite d'anticorps
JP2024539550A (ja) * 2021-09-29 2024-10-29 ナショナル リサーチ カウンシル オブ カナダ ヒト化抗ｅｇｆｒｖｉｉｉ抗体及びその抗原結合断片
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
JP2024538673A (ja) 2021-10-07 2024-10-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ｐＨモデリング及び制御のシステム及び方法
MX2024005090A (es) 2021-10-26 2024-07-19 Regeneron Pharma Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas.
EP4493921A1 (fr) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Procédés et systèmes permettant d'analyser des variants polypeptidiques
CN119546644A (zh) * 2022-05-18 2025-02-28 瑞泽恩制药公司 结合cd38和4-1bb的多特异性抗原结合分子及其用途
CN120418653A (zh) 2022-12-16 2025-08-01 里珍纳龙药品有限公司 评估色谱柱完整性的方法和系统
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
WO2024158961A1 (fr) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Caractérisation basée sur la spectrométrie de masse d'anticorps co-exprimés in vivo
WO2024163708A1 (fr) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Fractionnement en continu à flux asymétrique avec spectrométrie de masse pour analyse biomacromoléculaire
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
TW202506733A (zh) 2023-06-12 2025-02-16 美商安進公司 淋巴毒素β受體促效劑結合蛋白
CN121986113A (zh) * 2023-07-07 2026-05-05 美国政府(由卫生和人类服务部的部长所代表) 人源化40h3抗体
WO2025054406A1 (fr) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Procédés et systèmes d'évaluation de l'intégrité d'une colonne chromatographique
WO2025064403A2 (fr) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Procédés et systèmes pour développer des protocoles de chromatographie
CN121925272A (zh) 2023-09-29 2026-04-24 瑞泽恩制药公司 利用受控成核进行冻干
WO2025085594A1 (fr) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Purification rapide d'anticorps monoclonal à partir d'un matériau de culture cellulaire en amont dans un procédé
AU2024373307A1 (en) 2023-11-02 2026-05-14 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (fr) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Plateforme d'analyse par spectrométrie de masse à détection de charge d'aavs
WO2025175164A1 (fr) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Procédés de production de substances médicamenteuses formulées concentrées comprenant des protéines, et substance médicamenteuse formulée concentrée fabriquée par les procédés
WO2025194043A1 (fr) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate et polyoxyéthylène sorbitane utilisés en tant qu'excipients pour formulations de protéines stables
WO2025259840A1 (fr) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Procédés et systèmes de chromatographie mise à l'échelle
WO2026025058A1 (fr) 2024-07-25 2026-01-29 Regeneron Pharmaceuticals, Inc. Particules virales d'aav reciblées sur des cellules cancéreuses exprimant le r-egf
WO2026025028A1 (fr) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Procédés de fabrication de formulations protéiques à concentration ultra-élevée par lyophilisation
WO2026060350A1 (fr) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Procédés d'amélioration de la photostabilité et de contrôle de la formation d'espèces hmw dans des formulations biologiques, et formulations biologiques produites par les procédés
WO2026076201A2 (fr) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systèmes et procédés de production de protéines thérapeutiques par filtration tangentielle à passage unique pour la concentration en ligne et la réduction volumique de groupes de production
WO2026080597A1 (fr) 2024-10-08 2026-04-16 Regeneron Pharmaceuticals, Inc. Administration prolongée de produits biologiques et fabrication non aqueuse de ceux-ci

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA2066428C (fr) 1989-09-08 2000-11-28 Bert Vogelstein Modifications de la structure du gene recepteur du facteur de croissance epidermique dans les gliomes humains
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
AUPP380498A0 (en) 1998-05-29 1998-06-25 Biomolecular Research Institute Limited Egf receptor agonists and antagonists
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
US20040248196A1 (en) 2001-08-03 2004-12-09 Adams Timothy Edward Methods of screening based on the egf receptor crystal structure
US7736644B2 (en) * 2003-06-27 2010-06-15 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
EP1718667B1 (fr) 2004-02-23 2013-01-09 Genentech, Inc. Liants et conjugues heterocycliques auto-immolateurs
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
US20110142822A1 (en) 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008122039A2 (fr) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molécules d'anticorps hybrides médiées par la sélénocystéine
ES2731432T3 (es) 2007-05-23 2019-11-15 Ventana Med Syst Inc Transportadores poliméricos para inmunohistoquímica e hibridación in situ
WO2009067242A2 (fr) * 2007-11-20 2009-05-28 Imclone Llc Co-cristaux de fragment fab de l'anticorps 11f8 et du domaine extracellulaire de egfr et leurs utilisations
US20090269343A1 (en) * 2008-04-11 2009-10-29 Duke University Dual Specific Immunotoxin for Brain Tumor Therapy
RU2487877C2 (ru) 2008-04-30 2013-07-20 Иммьюноджен, Инк. Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры)
WO2010010324A1 (fr) 2008-07-21 2010-01-28 Polytherics Limited Nouveaux réactifs et procédé destiné à conjuguer des molécules biologiques
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
US8409838B2 (en) 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
WO2011018613A1 (fr) 2009-08-10 2011-02-17 Ucl Business Plc Fonctionnalisation de substrats solides
WO2011130598A1 (fr) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazépines et conjugués de celles-ci
WO2012005982A2 (fr) 2010-07-06 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Rapporteur pour une terminaison par la arn polymérase ii
TR201902180T4 (tr) * 2011-03-29 2019-03-21 Immunogen Inc Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi
EP2714685B1 (fr) 2011-05-27 2016-10-19 Ambrx, Inc. Compositions contenant des dérivés de dolastatine liés à des acides aminés non naturel
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9526798B2 (en) 2011-10-14 2016-12-27 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
SG11201401021TA (en) 2011-10-14 2014-08-28 Spirogen Sarl Pyrrolobenzodiazepines
US9102704B2 (en) 2011-10-14 2015-08-11 Spirogen Sarl Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
MX358757B (es) 2011-10-14 2018-09-03 Seattle Genetics Inc Pirrolobenzodiazepinas y conjugados dirigidos.
WO2013068874A1 (fr) 2011-11-11 2013-05-16 Pfizer Inc. Conjugués anticorps-médicament
HK1202252A1 (en) * 2011-11-16 2015-09-25 Amgen Inc. Methods of treating epidermal growth factor deletion mutant viii related disorders
AU2012348017A1 (en) 2011-12-05 2014-07-03 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
EP3964237B1 (fr) 2013-03-15 2026-02-18 Regeneron Pharmaceuticals, Inc. Molécules biologiquement actives, leurs conjugués, et utilisations thérapeutiques
HUE054057T2 (hu) * 2013-08-07 2021-08-30 Affimed Gmbh EGFRvIII specifikus antitest-kötõhelyek
MY178160A (en) 2014-03-11 2020-10-06 Regeneron Pharma Anti-egfrviii antibodies and uses thereof

Also Published As

Publication number Publication date
AU2015229591B2 (en) 2020-10-22
IL247407A0 (en) 2016-11-30
KR102399005B1 (ko) 2022-05-17
CL2016002252A1 (es) 2017-06-30
PL3126388T3 (pl) 2019-10-31
US20180312594A1 (en) 2018-11-01
JP2017510559A (ja) 2017-04-13
IL247407B (en) 2020-05-31
BR112016020752B1 (pt) 2023-11-14
BR112016020752A2 (pt) 2018-01-23
EA035809B1 (ru) 2020-08-14
EP3126388B1 (fr) 2019-05-08
PH12016501680B1 (en) 2016-10-24
US10738124B2 (en) 2020-08-11
MA39313A1 (fr) 2018-01-31
MY178160A (en) 2020-10-06
KR20160131026A (ko) 2016-11-15
EA201691824A1 (ru) 2016-12-30
HUE045307T2 (hu) 2019-12-30
DK3126388T3 (da) 2019-07-29
US20160304615A1 (en) 2016-10-20
ES2736126T3 (es) 2019-12-26
WO2015138460A1 (fr) 2015-09-17
SI3126388T1 (sl) 2019-08-30
US20210147557A1 (en) 2021-05-20
LT3126388T (lt) 2019-08-26
CA2940685A1 (fr) 2015-09-17
JP6632984B2 (ja) 2020-01-22
US11608380B2 (en) 2023-03-21
ZA201605894B (en) 2019-07-31
ME03525B (fr) 2020-04-20
US9475875B2 (en) 2016-10-25
MX373280B (es) 2020-04-16
PH12016501680A1 (en) 2016-10-24
CN106459199A (zh) 2017-02-22
US20150259423A1 (en) 2015-09-17
US10047160B2 (en) 2018-08-14
SMT201900439T1 (it) 2019-09-09
AU2015229591A1 (en) 2016-09-29
CY1121870T1 (el) 2020-10-14
CN106459199B (zh) 2021-01-01
RS59077B1 (sr) 2019-09-30
EP3126388A1 (fr) 2017-02-08
CA2940685C (fr) 2023-10-24
MX2016011619A (es) 2016-12-12
NZ724229A (en) 2023-06-30
PT3126388T (pt) 2019-08-20
SG11201606979TA (en) 2016-09-29
HRP20191335T1 (hr) 2019-10-18

Similar Documents

Publication Publication Date Title
MA39313A1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
MA46708B1 (fr) Anticorps anti-pd1 et leurs utilisations
ZA202201874B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MX392069B (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
CY1118668T1 (el) Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων
MA45280B1 (fr) Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
MA49727B1 (fr) Anticorps et polypeptides dirigés contre cd127
PL1830881T3 (pl) Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie
PH12021550120A1 (en) Chimeric receptors to steap1 and methods of use thereof
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
JOP20240021A1 (ar) الأجسام المضادة لمستقبل إنترلوكين-4 ألفا البشري
PH12019502717A1 (en) Recombinant robo2 proteins, compositions, methods and uses thereof
MX2020009864A (es) Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-1.
MA38848A1 (fr) Anticorps anti-prlr et utilisations associées
MA38302A1 (fr) Anticorps anti-pdgfr-bêta et leurs utilisations
MA41826B1 (fr) Anticorps anti-icos
MA38501B1 (fr) Anticorps humains de la protéine f du virus respiratoire syncytial et ses procédés d'utilisation
MA37464A1 (fr) Anticorps anti-egfr et leurs utilisations
MX2023003393A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
MA39751B1 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA38503A1 (fr) Anticorps anti-il-33 et leurs utilisations
MA41873B2 (fr) Anticorps anti-cd3, molécules de liaison à un antigène bispécifiques qui se lient à cd3 et cd20, et leurs utilisations
PE20131120A1 (es) Agentes citotoxicos mejorados que comprenden nuevos maitansinoides